X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GRWD5769 is the first-in-class ERAP1 inhibitor, being investigated as alone and in combination with libtayo for the treatment of advanced solid tumours.
Lead Product(s): GRWD5769,Cemiplimab
Therapeutic Area: Oncology Product Name: GRWD5769
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
Grey Wolf Therapeutics will use the net proceeds to Support Advancement of Lead Candidate, ERAP1 Inhibitor GRWD5769, into a Phase 1/2 clinical trial in the first half of 2023 and support the continued development of the company's first-of-its-kind immuno-oncology approaches.
Lead Product(s): GRWD5769,Cemiplimab
Therapeutic Area: Oncology Product Name: GRWD5769
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Ventures
Deal Size: $49.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 26, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
